Iqbal Multani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Iqbal Multani has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Jamil Manji
St. Paul's Sinus Centre, Vancouver, BC, Canada
3 shared publications - Michelle Ghert
Professor, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
3 shared publications - H. Kerr Graham
Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia
2 shared publications - Abhay Khot
Royal Children's Hospital, 50 Flemington Road, Parkville, VIC, 3052, Australia
1 shared publication - Anthony Bozzo
Faculty of Medicine and Health Sciences, McGill University
1 shared publication - Axel Öhlin
Division of Orthopaedic Surgery Department of Surgery McMaster University Hamilton Ontario Canada
1 shared publication
Latest Publications
- Open Access
- 12 August 2026
- Published by Wiley in Arthroscopy
- Vol. 42 (11) , 2818-2831
Hip Arthroscopy in Adults Aged 40 or Older Produces Clinically Meaningful Symptom Improvement but Carries a Substantial Risk of Conversion to Total Hip Arthroplasty: A Systematic Review
Purpose: To report conversion rates to total hip arthroplasty (THA), patient‐reported outcome measures, and complication rates in adults aged ≥ 40 years undergoing hip arthroscopy since 2016. Methods: MEDLINE, EMBASE, and PubMed were searched from January 2016 to March 2025, and pertinent data were abstracted from eligible studies according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. To provide an updated synthesis without duplicating prior work, this review was limited to studies published from 2016 onward, following a previous systematic review that comprehensively evaluated outcomes of hip arthroscopy in patients aged 40 years and older through 2015. Inclusion criteria were studies involving patients aged ≥ 40 years who underwent hip arthroscopy, published in English, and reporting at least 1 patient‐reported outcome measure or clinical outcome. Exclusion criteria included studies that were not Level I, II, or III studies with nonsurgical treatments or studies with duplicate patient cohorts. Results: Six studies were included (2 Level II cohort studies, 4 Level III cohort studies), encompassing 33,091 patients (30,549 ≥ 40 years; 92.3%). Among 5 studies (n = 2479), the overall THA conversion rate in patients ≥ 40 ranged from 5% to over 21%. The 2‐year THA conversion rate ranged from 9% to 13% in patients aged 40 to 60 years, and the 5‐year conversion rate was as high as 20.2%. Five studies reporting patient‐reported outcome measures showed significant improvements that exceeded the minimal clinically important difference at a follow‐up period of 2 years. Functional outcomes (Modified Harris Hip Score, Hip Outcome Score Activity of Daily Living Scale, Hip Outcome Score Sport Scale, and Nonarthritic Hip Score) were significantly worse in patients > 45 years compared with those < 45 years. Twenty‐one procedure‐related complications occurred among 1807 hips (1.16%) in patients 40 and older, the 2 most common being superficial soft‐tissue injuries (n = 4) and transient neuropraxia/nerve palsy (n = 3). Conclusions: Although hip arthroscopy continues to display statistically and clinically significant postoperative improvements in patients aged 40 and older, the risk of conversion to THA remains substantially higher compared with younger populations. Level of Evidence: Level III, systematic review of Level II and III studies.
- 12 August 2026
- Published by Wiley in Arthroscopy
- Vol. 42 (11) , 2818-2831
Open AccessHip Arthroscopy in Adults Aged 40 or Older Produces Clinically Meaningful Symptom Improvement but Carries a Substantial Risk of Conversion to Total Hip Arthroplasty: A Systematic Review
Purpose: To report conversion rates to total hip arthroplasty (THA), patient‐reported outcome measures, and complication rates in adults aged ≥ 40 years undergoing hip arthroscopy since 2016. Methods: MEDLINE, EMBASE, and PubMed were searched from January 2016 to March 2025, and pertinent data were abstracted from eligible studies according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. To provide an updated synthesis without duplicating prior work, this review was limited to studies published from 2016 onward, following a previous systematic review that comprehensively evaluated outcomes of hip arthroscopy in patients aged 40 years and older through 2015. Inclusion criteria were studies involving patients aged ≥ 40 years who underwent hip arthroscopy, published in English, and reporting at least 1 patient‐reported outcome measure or clinical outcome. Exclusion criteria included studies that were not Level I, II, or III studies with nonsurgical treatments or studies with duplicate patient cohorts. Results: Six studies were included (2 Level II cohort studies, 4 Level III cohort studies), encompassing 33,091 patients (30,549 ≥ 40 years; 92.3%). Among 5 studies (n = 2479), the overall THA conversion rate in patients ≥ 40 ranged from 5% to over 21%. The 2‐year THA conversion rate ranged from 9% to 13% in patients aged 40 to 60 years, and the 5‐year conversion rate was as high as 20.2%. Five studies reporting patient‐reported outcome measures showed significant improvements that exceeded the minimal clinically important difference at a follow‐up period of 2 years. Functional outcomes (Modified Harris Hip Score, Hip Outcome Score Activity of Daily Living Scale, Hip Outcome Score Sport Scale, and Nonarthritic Hip Score) were significantly worse in patients > 45 years compared with those < 45 years. Twenty‐one procedure‐related complications occurred among 1807 hips (1.16%) in patients 40 and older, the 2 most common being superficial soft‐tissue injuries (n = 4) and transient neuropraxia/nerve palsy (n = 3). Conclusions: Although hip arthroscopy continues to display statistically and clinically significant postoperative improvements in patients aged 40 and older, the risk of conversion to THA remains substantially higher compared with younger populations. Level of Evidence: Level III, systematic review of Level II and III studies.
- 23 March 2022
- Published by SAGE Publications in HAND
- Vol. 19 (1) , 12-23
The One-Bone Forearm: A Review
The one-bone forearm (OBF) is a salvage technique that may be used to correct global forearm instability secondary to osseous defects. This study aims to provide an overview of the contemporary literature regarding the OBF. A literature review was conducted electronically across MEDLINE, Embase, and PubMed databases in May 2020. Studies were eligible for inclusion if published in the English language; detailed the use of the OBF procedure to correct forearm instability; and were original data studies reporting qualitative or quantitative outcomes. Thirty-four studies, describing a cohort of 210 patients undergoing 211 OBFs, were documented in the literature. The primary etiology necessitating the OBF was trauma, followed by genetic/congenital disorders and infections. Technically, the OBF was most frequently achieved via an end-to-end osteosynthesis with plate fixation. In total, 85.0% (154/182) of OBF were fused in neutral rotation or varying degrees of pronation. Union was achieved in more than 80.0% (174/211) of OBFs. The OBF is a feasible salvage technique that has been used for a wide spectrum of pathology, providing satisfactory outcomes in most cases.
- 23 March 2022
- Published by SAGE Publications in HAND
- Vol. 19 (1) , 12-23
The One-Bone Forearm: A Review
The one-bone forearm (OBF) is a salvage technique that may be used to correct global forearm instability secondary to osseous defects. This study aims to provide an overview of the contemporary literature regarding the OBF. A literature review was conducted electronically across MEDLINE, Embase, and PubMed databases in May 2020. Studies were eligible for inclusion if published in the English language; detailed the use of the OBF procedure to correct forearm instability; and were original data studies reporting qualitative or quantitative outcomes. Thirty-four studies, describing a cohort of 210 patients undergoing 211 OBFs, were documented in the literature. The primary etiology necessitating the OBF was trauma, followed by genetic/congenital disorders and infections. Technically, the OBF was most frequently achieved via an end-to-end osteosynthesis with plate fixation. In total, 85.0% (154/182) of OBF were fused in neutral rotation or varying degrees of pronation. Union was achieved in more than 80.0% (174/211) of OBFs. The OBF is a feasible salvage technique that has been used for a wide spectrum of pathology, providing satisfactory outcomes in most cases.
- Open Access
- 26 February 2021
- Published by Frontiers Media SA in Oncology Reviews
- Vol. 15 (1) , 522
Published randomized controlled trials of surveillance in cancer patients - a systematic review
With solid tumor cancer survivorship increasing, the number of patients requiring post-treatment surveillance also continues to increase. This highlights the need for evidence-based cancer surveillance guidelines. Ideally, these guidelines would be based on combined high-quality data from randomized controlled trials (RCTs). We present a systematic review of published cancer surveillance RCTs in which we sought to determine the feasibility of data pooling for guideline development. We carried out a systematic search of medical databases for RCTs in which adult patients with solid tumors that had undergone surgical resection with curative intent and had no metastatic disease at presentation, were randomized to different surveillance regimens that assessed effectiveness on overall survival (OS). We extracted study characteristics and primary and secondary outcomes, and assessed risk of bias and validity of evidence with standardized checklist tools. Our search yielded 32,216 articles for review and 18 distinct RCTs were included in the systematic review. The 18 trials resulted in 23 comparisons of surveillance regimens. There was a highlevel of variation between RCTs, including the study populations evaluated, interventions assessed and follow-up periods for the primary outcome. Most studies evaluated colorectal cancer patients (11/18, [61%]). The risk of bias and validity of evidence were variable and inconsistent across studies. This review demonstrated that there is tremendous heterogeneity among RCTs that evaluate effectiveness of different postoperative surveillance regimens in cancer patients, rendering the consolidation of data to inform high-quality cancer surveillance guidelines unfeasible. Future RCTs in the field should focus on consistent methodology and primary outcome definition.
- 26 February 2021
- Published by Frontiers Media SA in Oncology Reviews
- Vol. 15 (1) , 522
Open AccessPublished randomized controlled trials of surveillance in cancer patients - a systematic review
With solid tumor cancer survivorship increasing, the number of patients requiring post-treatment surveillance also continues to increase. This highlights the need for evidence-based cancer surveillance guidelines. Ideally, these guidelines would be based on combined high-quality data from randomized controlled trials (RCTs). We present a systematic review of published cancer surveillance RCTs in which we sought to determine the feasibility of data pooling for guideline development. We carried out a systematic search of medical databases for RCTs in which adult patients with solid tumors that had undergone surgical resection with curative intent and had no metastatic disease at presentation, were randomized to different surveillance regimens that assessed effectiveness on overall survival (OS). We extracted study characteristics and primary and secondary outcomes, and assessed risk of bias and validity of evidence with standardized checklist tools. Our search yielded 32,216 articles for review and 18 distinct RCTs were included in the systematic review. The 18 trials resulted in 23 comparisons of surveillance regimens. There was a highlevel of variation between RCTs, including the study populations evaluated, interventions assessed and follow-up periods for the primary outcome. Most studies evaluated colorectal cancer patients (11/18, [61%]). The risk of bias and validity of evidence were variable and inconsistent across studies. This review demonstrated that there is tremendous heterogeneity among RCTs that evaluate effectiveness of different postoperative surveillance regimens in cancer patients, rendering the consolidation of data to inform high-quality cancer surveillance guidelines unfeasible. Future RCTs in the field should focus on consistent methodology and primary outcome definition.
- Open Access
- 7 September 2020
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2020, 1-4
Extraskeletal Myxoid Chondrosarcoma: Long-Term Survival in the Setting of Metastatic Disease
Three cases of extraskeletal myxoid chondrosarcoma (EMC) in patients who presented with pulmonary metastases and were managed with long-term close observation without systemic intervention are presented. Follow-up imaging showed slow progression of their disease over several years, and the patients remained asymptomatic from their pulmonary metastases. This clinical experience provides insight into the natural history of the disease and suggests that some patients may experience long-term survival and remain asymptomatic even without systemic intervention, thereby improving their quality of life by avoiding potentially debilitating treatments.
- 7 September 2020
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2020, 1-4
Open AccessExtraskeletal Myxoid Chondrosarcoma: Long-Term Survival in the Setting of Metastatic Disease
Three cases of extraskeletal myxoid chondrosarcoma (EMC) in patients who presented with pulmonary metastases and were managed with long-term close observation without systemic intervention are presented. Follow-up imaging showed slow progression of their disease over several years, and the patients remained asymptomatic from their pulmonary metastases. This clinical experience provides insight into the natural history of the disease and suggests that some patients may experience long-term survival and remain asymptomatic even without systemic intervention, thereby improving their quality of life by avoiding potentially debilitating treatments.
- Open Access
- 1 August 2019
- Published by Wolters Kluwer Health in JBJS Reviews
- Vol. 7 (8) , e4
Sarcopenia, Cerebral Palsy, and Botulinum Toxin Type A
» Sarcopenia is common in both the elderly and children with cerebral palsy. » Children with cerebral palsy have muscles that are much smaller than muscles in typically developing peers. » Injections of botulinum toxin type A (BoNT-A) result in acute muscle atrophy in animal models and in human subjects. » It is not known when or if muscles recover fully after injection of BoNT-A. » These findings have implications for management protocols.
- 1 August 2019
- Published by Wolters Kluwer Health in JBJS Reviews
- Vol. 7 (8) , e4
Open AccessSarcopenia, Cerebral Palsy, and Botulinum Toxin Type A
» Sarcopenia is common in both the elderly and children with cerebral palsy. » Children with cerebral palsy have muscles that are much smaller than muscles in typically developing peers. » Injections of botulinum toxin type A (BoNT-A) result in acute muscle atrophy in animal models and in human subjects. » It is not known when or if muscles recover fully after injection of BoNT-A. » These findings have implications for management protocols.
- Top Cited PapersOpen Access
- 1 July 2019
- Published by Springer Nature in Pediatric Drugs
- Vol. 21 (4) , 261-281
Botulinum Toxin in the Management of Children with Cerebral Palsy
During the past 25 years, botulinum toxin type A (BoNT-A) has become the most widely used medical intervention in children with cerebral palsy. In this review we consider the gaps in our knowledge in the use of BoNT-A and reasons why muscle morphology and function in children with cerebral palsy are impaired. We review limitations in our knowledge regarding the mechanisms underlying the development of contractures and the difficulty in preventing them. It is clear from this review that injection of BoNT-A in the large muscles of both the upper and lower limbs of children with cerebral palsy will result in a predictable decrease in muscle activity, which is usually reported as a reduction in spasticity, for between 3 and 6 months. These changes are noted by the use of clinical tools such as the Modified Ashworth Scale and the Modified Tardieu Scale. Decreased muscle over-activity usually results in improved range of motion in distal joints. Injection of the gastrocnemius muscle for toe-walking in a child with hemiplegia or diplegia usually has the effect of increasing the passive range of dorsiflexion at the ankle. In our review, we found that this may result in a measurable improvement in gait by the use of observational gait scales or gait analysis, in some children. However, improvements in gait function are not always achieved and are small in magnitude and short lived. We found that some of the differences in outcomes in clinical trials may relate to the use of adjunctive interventions such as serial casting, orthoses, night splints and intensive therapy. We note that the majority of clinical trials of the use of BoNT-A in children with cerebral palsy have focussed on a single injection cycle and this is insufficient to understand the balance between benefit and harm. Most outcomes were reported in terms of changes in muscle tone and there were fewer studies with robust methodology that reported improvements in function. Changes in the domains of activities and participation have rarely been reported in studies to date. There were no clinical reviews to date that consider the findings of studies in human volunteers and in experimental animals and their relevance to clinical protocols. In this review we found that studies in human volunteers and in experimental animals show muscle atrophy after an injection of BoNT-A for at least 12 months. Muscle atrophy was accompanied by loss of contractile elements in muscle and replacement with fat and connective tissue. It is not currently known if these changes, mediated at a molecular level, are reversible. We conclude that there is a need to revise clinical protocols by using BoNT-A more thoughtfully, less frequently and with greatly enhanced monitoring of the effects on injected muscle for both short-term and long-term benefits and harms.
- 1 July 2019
- Published by Springer Nature in Pediatric Drugs
- Vol. 21 (4) , 261-281
Top Cited PapersOpen AccessBotulinum Toxin in the Management of Children with Cerebral Palsy
During the past 25 years, botulinum toxin type A (BoNT-A) has become the most widely used medical intervention in children with cerebral palsy. In this review we consider the gaps in our knowledge in the use of BoNT-A and reasons why muscle morphology and function in children with cerebral palsy are impaired. We review limitations in our knowledge regarding the mechanisms underlying the development of contractures and the difficulty in preventing them. It is clear from this review that injection of BoNT-A in the large muscles of both the upper and lower limbs of children with cerebral palsy will result in a predictable decrease in muscle activity, which is usually reported as a reduction in spasticity, for between 3 and 6 months. These changes are noted by the use of clinical tools such as the Modified Ashworth Scale and the Modified Tardieu Scale. Decreased muscle over-activity usually results in improved range of motion in distal joints. Injection of the gastrocnemius muscle for toe-walking in a child with hemiplegia or diplegia usually has the effect of increasing the passive range of dorsiflexion at the ankle. In our review, we found that this may result in a measurable improvement in gait by the use of observational gait scales or gait analysis, in some children. However, improvements in gait function are not always achieved and are small in magnitude and short lived. We found that some of the differences in outcomes in clinical trials may relate to the use of adjunctive interventions such as serial casting, orthoses, night splints and intensive therapy. We note that the majority of clinical trials of the use of BoNT-A in children with cerebral palsy have focussed on a single injection cycle and this is insufficient to understand the balance between benefit and harm. Most outcomes were reported in terms of changes in muscle tone and there were fewer studies with robust methodology that reported improvements in function. Changes in the domains of activities and participation have rarely been reported in studies to date. There were no clinical reviews to date that consider the findings of studies in human volunteers and in experimental animals and their relevance to clinical protocols. In this review we found that studies in human volunteers and in experimental animals show muscle atrophy after an injection of BoNT-A for at least 12 months. Muscle atrophy was accompanied by loss of contractile elements in muscle and replacement with fat and connective tissue. It is not currently known if these changes, mediated at a molecular level, are reversible. We conclude that there is a need to revise clinical protocols by using BoNT-A more thoughtfully, less frequently and with greatly enhanced monitoring of the effects on injected muscle for both short-term and long-term benefits and harms.
- Open Access
- 28 May 2019
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2019, 1-5
Osteosarcomatous Transformation in the Setting of Mazabraud’s Syndrome: A Case Report and Review of the Literature
Introduction. Mazabraud’s Syndrome is a rare condition that is defined by the presence of fibrous dysplasia lesions in the bone and intramuscular myxomas in the soft tissue. Malignant transformation, in the setting of Mazabraud’s Syndrome, of the fibrous dysplasia lesions into a sarcomatous neoplasm occurs in less than 1% of cases—with only six previously reported cases. Case Presentation. Here, we present a 62-year-old Caucasian female who developed an osteosarcoma in a fibrous dysplasia lesion of the proximal femur in the background of Mazabraud’s Syndrome. The patient was treated with wide excision and endoprosthetic reconstruction. She declined adjuvant chemotherapy. She is alive without evidence of disease one-year postoperatively. Conclusion. Patients with Mazabraud’s Syndrome remain at low risk for malignant transformation. However, close monitoring of asymptomatic patients with this condition for radiographic changes in their lesions and/or clinical symptoms is recommended.
- 28 May 2019
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2019, 1-5
Open AccessOsteosarcomatous Transformation in the Setting of Mazabraud’s Syndrome: A Case Report and Review of the Literature
Introduction. Mazabraud’s Syndrome is a rare condition that is defined by the presence of fibrous dysplasia lesions in the bone and intramuscular myxomas in the soft tissue. Malignant transformation, in the setting of Mazabraud’s Syndrome, of the fibrous dysplasia lesions into a sarcomatous neoplasm occurs in less than 1% of cases—with only six previously reported cases. Case Presentation. Here, we present a 62-year-old Caucasian female who developed an osteosarcoma in a fibrous dysplasia lesion of the proximal femur in the background of Mazabraud’s Syndrome. The patient was treated with wide excision and endoprosthetic reconstruction. She declined adjuvant chemotherapy. She is alive without evidence of disease one-year postoperatively. Conclusion. Patients with Mazabraud’s Syndrome remain at low risk for malignant transformation. However, close monitoring of asymptomatic patients with this condition for radiographic changes in their lesions and/or clinical symptoms is recommended.